Mediwound (MDWD) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
MediWound has reported a significant milestone with FDA approval for pediatric use of its burn treatment, NexoBrid, while also progressing with its Phase 3 trial for EscharEx targeting venous leg ulcers. Despite a decrease in quarterly revenue to $4.4 million and a notable increase in net loss primarily due to warrant revaluation, the company secured substantial financing, including a $25 million PIPE investment and €16.25 million from the EIC, to bolster its financial position and expand its manufacturing capabilities.
For further insights into MDWD stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Shareholder Alert for PACS Group, Inc. (NYSE:PACS)
- Netflix Wins Shareholder Lawsuit Alleging Misleading Growth Forecasts
- OpenAI’s Text-Video Generator Sora Leaked by Artists in Protest
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
